What is HC Wainwright’s Estimate for Geron Q4 Earnings?

Geron Co. (NASDAQ:GERN) – Investment analysts at HC Wainwright issued their Q4 2024 earnings per share estimates for Geron in a research note issued to investors on Tuesday, November 5th. HC Wainwright analyst E. Bodnar anticipates that the biopharmaceutical company will earn ($0.08) per share for the quarter. HC Wainwright has a “Buy” rating and a $8.00 price objective on the stock. The consensus estimate for Geron’s current full-year earnings is ($0.34) per share. HC Wainwright also issued estimates for Geron’s FY2026 earnings at ($0.13) EPS, FY2027 earnings at $0.05 EPS and FY2028 earnings at $0.35 EPS.

A number of other research firms have also weighed in on GERN. Needham & Company LLC reissued a “buy” rating and set a $6.00 price objective on shares of Geron in a research note on Friday, August 9th. Leerink Partners assumed coverage on Geron in a research note on Monday, September 9th. They set an “outperform” rating and a $7.00 price objective for the company. StockNews.com raised Geron to a “sell” rating in a research note on Monday, August 5th. Scotiabank began coverage on Geron in a research note on Wednesday, October 16th. They set a “sector outperform” rating and a $6.00 price objective for the company. Finally, Wedbush restated an “outperform” rating and set a $8.00 target price on shares of Geron in a report on Thursday, August 8th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Geron currently has a consensus rating of “Moderate Buy” and an average target price of $7.05.

Geron Stock Performance

NASDAQ:GERN opened at $4.27 on Thursday. Geron has a fifty-two week low of $1.64 and a fifty-two week high of $5.34. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.61 and a quick ratio of 3.60. The business has a 50 day moving average price of $4.33 and a 200-day moving average price of $4.30.

Geron (NASDAQ:GERN) last issued its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.10). The business had revenue of $0.88 million during the quarter, compared to analyst estimates of $0.34 million. Geron had a negative return on equity of 73.79% and a negative net margin of 15,990.68%. Geron’s revenue for the quarter was up 2941.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.09) earnings per share.

Hedge Funds Weigh In On Geron

A number of institutional investors have recently added to or reduced their stakes in GERN. National Bank of Canada FI raised its holdings in Geron by 1,200.0% in the second quarter. National Bank of Canada FI now owns 6,500 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 6,000 shares in the last quarter. Crewe Advisors LLC raised its holdings in Geron by 870.0% in the first quarter. Crewe Advisors LLC now owns 9,700 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 8,700 shares in the last quarter. Kingsview Wealth Management LLC bought a new position in Geron in the first quarter worth $34,000. American Trust bought a new position in Geron in the first quarter worth $38,000. Finally, Rovin Capital UT ADV bought a new position in Geron in the third quarter worth $62,000. Institutional investors own 73.71% of the company’s stock.

About Geron

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.